Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)
Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
A PHASE1 clinical study on Non-small Cell Lung Cancer (NSCLC), this trial is completed. The trial is conducted by H. Lee Moffitt Cancer Center and Research Institute and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed · Phase: PHASE1_PHASE2 → PHASE1
-
Jan 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Dec 2018 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- H. Lee Moffitt Cancer Center and Research Institute
- Novartis
- Palobiofarma SL
For direct contact, visit the study record on ClinicalTrials.gov .